Q-omics provides the consensus-scored ANGPT4 profile across patient tissues and cancer cell-line models. ANGPT4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ANGPT4 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ANGPT4 RNA expression shows 13,039 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, THCA, and TGCT as cancer lineages where ANGPT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGPT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGPT4 survival associations across molecular data types. ANGPT4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGPT4 RNA expression–survival associations across cancer types. High ANGPT4 expression shows unfavorable associations in OV, UCS, STAD and UCEC, but favorable associations in KIRC and LIHC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify OV as the clearest survival context for ANGPT4 RNA expression.
This table summarizes ANGPT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANGPT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGPT4 shows lower tumor expression in THCA, BLCA, LUSC, LUAD, BRCA and UCEC. The THCA box plot shows higher ANGPT4 RNA expression in normal versus tumor tissue (log2 FC = −0.910, t-test p < 0.001).
This table shows molecular features associated with ANGPT4 in patient tissues and cancer cell lines. In patient samples, ANGPT4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGPT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
